MD Anderson cancer Centre
Welcome,         Profile    Billing    Logout  
 61 Trials 
60 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Naing, Aung
NCT05672459: A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

Recruiting
1/2
117
US
Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide, leukapheresis
M.D. Anderson Cancer Center, Invectys
Solid Tumor
06/26
12/29
NCT05584670: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Recruiting
1/2
285
Europe, US, RoW
SAR445877, Cetuximab, Erbitux
Sanofi
Solid Tumor
01/27
09/28
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Recruiting
1a/1b
198
Europe, US
NG-350A plus Pembrolizumab
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
NCT04306224: A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Completed
1
12
US, RoW
IMC-002
ImmuneOncia Therapeutics Inc.
Solid Tumor, Lymphoma
10/22
10/22
NCT04859777: A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Recruiting
1
70
US
MPT-0118, MPT-0118 + pembrolizumab
Monopteros Therapeutics Inc.
Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
03/23
03/23
AURELIO-03, NCT04234113: Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Active, not recruiting
1
200
Europe, US, RoW
SO-C101, SOT101, pembrolizumab
SOTIO Biotech AG, SOTIO Biotech a.s.
Thyroid, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer
08/24
11/24
NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed
1
91
US
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy
Immune-Onc Therapeutics, Regeneron Pharmaceuticals
Solid Tumor, Adult
04/24
05/24
NPX887-001, NCT06240728: A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7

Recruiting
1
144
US
NPX887
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
08/27
08/27
NCT05309187: Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Completed
1
22
US
IO-202, IO-202 + pembrolizumab combination therapy, IO-202 + Keytruda combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types, RP2D of IO-202 + Keytruda combination therapy
Immune-Onc Therapeutics
Solid Tumor, Adult
03/24
05/24
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
NCT06163391: A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

Recruiting
1
40
Europe, US, RoW
SOT201
SOTIO Biotech AG
Advanced Solid Tumor, Metastatic Solid Tumor
10/26
10/26
NCT05669430: A Study of GV20-0251 in Patients With Solid Tumor Malignancies

Recruiting
1
268
US
GV20-0251
GV20 Therapeutics
Solid Tumor, Adult, Refractory Cancer, Bladder Urothelial Carcinoma, Cholangiocarcinoma, Adenocarcinoma of the Colon, Endometrial Carcinoma, Head and Neck Carcinoma, Cutaneous Melanoma, Non-small Cell Lung Cancer, Adenocarcinoma of the Rectum
12/25
06/26
NCT05958199: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Recruiting
1
131
US
NPX267
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
01/26
01/26
NCT06046066: A Phase 1 Study of NM6603 in Advanced Solid Tumors

Recruiting
1
36
US
NM6603
NucMito Pharmaceuticals Co. Ltd.
Cancers
02/26
07/26
Piha-Paul, Sarina
NCT05500508: Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Recruiting
1b/2a
56
US, RoW
AMXT1501, DFMO, difluoromethyl ornithine monohydrochloride
Aminex Therapeutics, Inc.
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
06/24
09/24
ENBolden-101, NCT04205227: ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

Active, not recruiting
1b/2a
137
US, RoW
ENB003, Pembrolizumab, Keytruda, MK-3475
ENB Therapeutics, Inc, Merck Sharp & Dohme LLC
Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer, Solid Tumor
01/26
03/26
NCT04742959: Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Completed
1/2
203
US
TT-00420, Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
02/24
02/24
INCLINE-101, NCT05399654: A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Recruiting
1/2
200
US, RoW
TAC-001
Tallac Therapeutics
Advanced or Metastatic Solid Tumors
01/26
05/26
NCT05443126: A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting
1/2
265
Europe, US
EP0031
Ellipses Pharma
Advanced Solid Tumor
12/26
06/27
NCT03654547: Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

Active, not recruiting
1
48
US, RoW
TT-00420
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumors, Triple Negative Breast Cancer
01/23
02/24
NCT03518554: A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Recruiting
1
45
US
JAB-3068
Jacobio Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
07/21
07/21
NCT04834778: A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

Completed
1
23
US
HC-5404-FU, HC-5404
HiberCell, Inc., Covance
Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
12/23
01/24
KEYNOTE-C82, NCT04648202: FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Recruiting
1
277
Europe, US
FS120, Pembrolizumab (KEYTRUDA®)
invoX Pharma Limited, Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
03/26
03/26
NCT05431270: Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1
40
US
PT199, Tislelizumab
Phanes Therapeutics
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/24
08/25
NCT05234853: Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors

Recruiting
1
23
US
PUR001
Purinomia Biotech, Inc.
Advanced Solid Tumors
12/23
12/23
NCT04735978: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Active, not recruiting
1
123
Europe, US
RP3, Nivolumab
Replimune Inc., Bristol-Myers Squibb
Advanced Solid Tumor
04/24
04/24
NCT05306444: CLN-418 Study on Subjects With Advanced Solid Tumors

Recruiting
1
108
US, RoW
CLN-418, HBM7008
Cullinan Oncology Inc., Harbour BioMed US, Inc.
Advanced Solid Tumor
06/24
06/24
NCT05569057: A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Recruiting
1
100
US
SIM1811-03, SIM0235, TNFR2 monoclonal antibody
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
06/24
03/25
NCT05488548: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors

Recruiting
1
50
US
EP31670, NEO2734
Epigenetix, Inc.
Castrate Resistant Prostate Cancer, NUT Carcinoma
06/24
09/24
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
824
Europe, US
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
11/26
10/28
NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Terminated
1
53
US
ABM-1310, ABM1310, Cobimetinib, Cotellic®
ABM Therapeutics Corporation
Advanced Solid Tumor, BRAF V600 Mutation
04/24
04/24
NCT03435952: Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Active, not recruiting
1
18
US
Pembrolizumab, Keytruda, MK-3475, SCH-900475, Clostridium Novyi-NT, Doxycycline, Vibramycin, Periostat, Doryx
M.D. Anderson Cancer Center, BioMed Valley Discoveries, Inc, Merck Sharp & Dohme LLC
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasms of Respiratory and Intrathoracic Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract
10/24
10/24
NCT05781360: A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors

Recruiting
1
192
US, RoW
SIM0237
Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai Xianxiang Medical Technology Co., Ltd., Simcere Zaiming
Locally Advanced Unresectable or Metastatic Solid Tumor
04/25
01/26
KEYNOTE-E92, NCT05378425: A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Recruiting
1
90
US, RoW
NTX-1088, Pembrolizumab, KEYTRUDA®
Nectin Therapeutics Ltd, Merck Sharp & Dohme LLC
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
06/25
12/25
NCT05831995: Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.

Recruiting
1
112
US
ABM-168
ABM Therapeutics Corporation
Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
10/25
10/25
ON-5001, NCT06022029: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Recruiting
1
168
US
ONM-501, Cemiplimab, Libtayo
OncoNano Medicine, Inc.
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
04/26
08/26
Diab, Adi
ATLAS-IT-05, NCT04796194: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Active, not recruiting
2
20
Europe, US
LTX-315 in combination with pembrolizumab
Lytix Biopharma AS, Laboratory Corporation of America, OWL
Advanced Melanoma
12/24
12/24
NCT02706353: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Active, not recruiting
1/2
32
US
APX005M, Pembrolizumab, Keytruda, MK-3475, SCH-900475
M.D. Anderson Cancer Center, Apexigen America, Inc., Pyxis Oncology
Melanoma
04/25
04/25
NCT06035744: CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
1
86
US
CLN-617, Pembrolizumab, Keytruda
Cullinan Therapeutics Inc.
Advanced Solid Tumor
06/28
06/28
Evans, Mererid
MOAT, NCT04830592: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck

Recruiting
1
36
Europe
NG-641, Pembrolizumab
Akamis Bio
Squamous Cell Carcinoma of the Head and Neck
09/24
10/24
Thompson, Alastair
MAGELLAN, NCT03796559: Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

Recruiting
N/A
65
US
Magseed Marker
Endomagnetics Inc, M.D. Anderson Cancer Center
Breast Cancer, Axillary Lymph Nodes
12/24
04/25
RCT, NCT05113927: Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Recruiting
N/A
531
US
Selene
Perimeter Medical Imaging, Cancer Prevention Research Institute of Texas, Proxima Clinical Research, Biostatistical Consulting, Inc.
Breast Cancer
10/24
01/25
ANGEL, NCT06085833: ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Recruiting
N/A
2706
US
Nanomechanical Phenotype Test
ARTIDIS AG
Breast Cancer
10/25
11/35
PREDICT, NCT03448926: The Registry for DCIS Patients With DCISionRT Testing

Suspended
N/A
2500
US, RoW
Treatment Recommendation Surveys
PreludeDx, University of South Florida
DCIS
11/25
11/35
Khan, Rabia
NCT05500508: Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Recruiting
1b/2a
56
US, RoW
AMXT1501, DFMO, difluoromethyl ornithine monohydrochloride
Aminex Therapeutics, Inc.
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
06/24
09/24
ENBolden-101, NCT04205227: ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

Active, not recruiting
1b/2a
137
US, RoW
ENB003, Pembrolizumab, Keytruda, MK-3475
ENB Therapeutics, Inc, Merck Sharp & Dohme LLC
Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer, Solid Tumor
01/26
03/26
NCT05074472: A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

Completed
1/2
35
US
ZB131
ZielBio, Inc.
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic, Ovarian Serous Cystadenocarcinoma
08/23
09/23
STX-001-01, NCT06249048: Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Recruiting
1/2
108
US, RoW
STX-001, Keytruda®, Pembrolizumab
Strand Therapeutics Inc.
Advanced Solid Tumor
05/27
11/28
NCT05431270: Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1
40
US
PT199, Tislelizumab
Phanes Therapeutics
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/24
08/25
NCT05234853: Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors

Recruiting
1
23
US
PUR001
Purinomia Biotech, Inc.
Advanced Solid Tumors
12/23
12/23
NCT05539157: Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Active, not recruiting
1
1
US
JCXH-211
Immorna Biotherapeutics, Inc.
Cutaneous Tumor, Malignant Solid Tumor
03/24
05/24
NCT05488548: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors

Recruiting
1
50
US
EP31670, NEO2734
Epigenetix, Inc.
Castrate Resistant Prostate Cancer, NUT Carcinoma
06/24
09/24
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
824
Europe, US
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
11/26
10/28
NX-1607-101, NCT05107674: A Study of NX-1607 in Adults With Advanced Malignancies

Recruiting
1
345
Europe, US
NX-1607, Cbl-b Inhibitor, Paclitaxel
Nurix Therapeutics, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
08/24
02/26
NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Terminated
1
53
US
ABM-1310, ABM1310, Cobimetinib, Cotellic®
ABM Therapeutics Corporation
Advanced Solid Tumor, BRAF V600 Mutation
04/24
04/24
NCT05831995: Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.

Recruiting
1
112
US
ABM-168
ABM Therapeutics Corporation
Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
10/25
10/25
Gurses, Serdar
STX-001-01, NCT06249048: Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Recruiting
1/2
108
US, RoW
STX-001, Keytruda®, Pembrolizumab
Strand Therapeutics Inc.
Advanced Solid Tumor
05/27
11/28
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Recruiting
1a/1b
198
Europe, US
NG-350A plus Pembrolizumab
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
STARLING, NCT05576077: A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
1
60
Canada, US
TBio-4101, TIL, autologous, tumor-reactive, T-cell product, Pembrolizumab, Keytruda
Turnstone Biologics, Corp.
Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
12/24
06/25

Download Options